Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.

Literature DB >> 27501841

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.

Maria Del Castillo¹, Fabian A Romero², Esther Argüello², Chrisann Kyi³, Michael A Postow², Gil Redelman-Sidi².

Abstract

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

Entities: Disease Species

Keywords: checkpoint blockade; immunotherapy; infection; melanoma

Mesh：

Substances：

Year: 2016 PMID： 27501841 PMCID： PMC5106605 DOI： 10.1093/cid/ciw539

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

24 in total

1. Ipilimumab-induced colitis in patients with metastatic melanoma.

Authors: Kara M De Felice; Arjun Gupta; Sagar Rakshit; Sahil Khanna; Lisa A Kottschade; Heidi D Finnes; Konstantinos A Papadakis; Edward V Loftus; Laura E Raffals; Svetomir N Markovic
Journal: Melanoma Res Date: 2015-08 Impact factor: 3.599

2. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245

Review 3. Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors: Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544

4. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors: Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544

5. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Authors: Y B Su; Sejean Sohn; Susan E Krown; Philip O Livingston; Jedd D Wolchok; Carolyn Quinn; Linda Williams; Theresa Foster; Kent A Sepkowitz; Paul B Chapman
Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544

6. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

7. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079

8. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Authors: Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark
Journal: JAMA Oncol Date: 2016-02 Impact factor: 31.777

Review 9. Checkpoint Blockade for the Treatment of Advanced Melanoma.

Authors: Margaret K Callahan; Catherine R Flaherty; Michael A Postow
Journal: Cancer Treat Res Date: 2016

10. Opportunistic infections in patients treated with immunotherapy for cancer.

Authors: Chrisann Kyi; Matthew D Hellmann; Jedd D Wolchok; Paul B Chapman; Michael A Postow
Journal: J Immunother Cancer Date: 2014-06-18 Impact factor: 13.751

68 in total

Review 1. [The pathology of adverse events with immune checkpoint inhibitors].

Authors: V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal: Pathologe Date: 2017-05 Impact factor: 1.011

2. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis.

Authors: Hajir Ibraheim; Michael Green; Sophie Papa; Nick Powell
Journal: BMJ Case Rep Date: 2019-04-03

Review 3. Checkpoint Inhibitors.

Authors: Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal: Dtsch Arztebl Int Date: 2019-02-22 Impact factor: 5.594

Review 4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors: G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal: Clin Microbiol Infect Date: 2018-02-07 Impact factor: 8.067

Review 5. Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors.

Authors: Xin Li; Susanna Kp Lau; Patrick Cy Woo
Journal: Exp Biol Med (Maywood) Date: 2020-07-08

6. Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?

Authors: Daniele Focosi; Marco Tuccori; Fabrizio Maggi
Journal: Ann Transl Med Date: 2019-12

7. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).

Authors: M Majem; E García-Martínez; M Martinez; E Muñoz-Couselo; D Rodriguez-Abreu; R Alvarez; A Arance; A Berrocal; L de la Cruz-Merino; J A Lopez-Martin
Journal: Clin Transl Oncol Date: 2020-01-28 Impact factor: 3.405